The case highlights concerns that a network of
individual gene patents could threaten the future of personalized medicine and whole - genome sequencing by blocking companies and clinicians from reporting a patient's genetic risk factors for different diseases.
The Supreme Court of Canada determined in 2002 that one could not
patent a higher life form (an altered mouse having cancer
genes), however
individual cells were patentable (Harvard College v CIPO 2002 SCC 76).